Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | GRK2 | P25098 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144080 | 0.88 | KDR (0.47) | KDRROCK2ROCK1LMNAMAPK1 | |
| SCHEMBL8062317 | 0.83 | CLK1 (0.43) | LMNAALDH1A1HPGDMAPTKMT2A | |
| SCHEMBL7145106 | 0.81 | ROCK2 (0.48) | KDREGLN2EGLN1ROCK2ROCK1 | |
| SCHEMBL7145508 | 0.80 | ROCK2 (0.53) | KDREGLN2EGLN1ROCK2ROCK1 | |
| SCHEMBL7145773 | 0.80 | ROCK2 (0.53) | KDRROCK2ROCK1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7145017 | 0.79 | ROCK2 (0.52) | KDREGLN2EGLN1ROCK2ROCK1 | |
| SCHEMBL7140468 | 0.79 | ROCK2 (0.54) | EGLN2EGLN1ROCK2ROCK1LMNA | |
| Trifluoroacetic Acid SCHEMBL7145403 | 0.79 | NR1H4 (0.45) | MAPK1HTTMAPTKDM4EGAA | |
| SCHEMBL6776908 | 0.78 | MAPK1 (0.50) | KDREGLN2EGLN1LMNAMAPK1 | |
| SCHEMBL7141146 | 0.77 | ROCK2 (0.59) | KDRROCK2ROCK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | claimed |
| EP-0928790-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-05 | — | — | EP | disclosed |
| US-6344562-B1 | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2002-02-05 | — | — | US | disclosed |
| US-20020010316-A1 | Thiazole derivatives | ALIG LEO (CH) | 2002-01-24 | — | — | US | disclosed |
| US-6320054-B1 | INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. | HOFFMAN-LA ROCHE INC. | 2001-11-20 | — | — | US | disclosed |
| US-6100282-A | Thiazole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2000-08-08 | — | — | US | disclosed |
| EP-0928790-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010316-A1 | Thiazole derivatives | VCAM1, SOST, TGFB1 | KDR 12/4885EGLN2 4211/4885EGLN1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.